bispecific antibody Clinical Research Trials

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (2)

Phase 1/2 (2)

Interventional (2)

Akeso (1)
BeiGene (1)

No (2)

No (2)

Adult (18+) (2)

I am/have/had

I am/have/hadepidermal growth factor

I am/have/hadEGFR

I am/have/haderbb2

I am/have/hadgastric adenocarcinoma

I am/have/hadcancer treatment

I am/have/hadbreast cancer

I am/have/hadcytotoxic chemotherapy

I am/have/hadcancer therapy

I am/have/hadadenocarcinoma of the gastroesophageal junction

I am/have/hadt-cell lymphoma

I am/have/hadlymphoma

I am/have/hadepidermal growth factor receptor

I am/have/hadcancer

I am/have/hadHER2

I am/have/hadher1

I am/have/hadglomerular filtration rate

I am/have/hadadenocarcinoma

I am/have/hadperipheral t-cell lymphoma

I am/have/hadrefractory peripheral t-cell lymphoma

I am/have/hadbreast cancer, treatment

added new label for I am/have/had

I am looking for

I am looking forepidermal growth factor

I am looking forgrowth factor

I am looking forerbb2

I am looking forbispecific antibody

I am looking foroxaliplatin

I am looking fortislelizumab

I am looking forhuman epidermal growth factor

I am looking forcapecitabine

I am looking fordocetaxel

added new label for I am looking for

Advanced Filters

Found 2 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Multi-country trial
Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Family Medicine
Recruiting

Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab

The purpose of the study is to assess the safety, tolerability and preliminary antitumor activity of ZW25 in combination with docetaxel in participants with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and ZW25 in combination with tislelizumab and chemotherapy in participants with HER2-positive gastric/gastroesophageal Junction (GEJ) adenocarcinoma

EGFR

erbb2

bispecific antibody

breast cancer

oxaliplatin

0 views
19 Feb, 2024

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Hematology
Recruiting

A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

The purpose of this study is to evaluate the efficacy and safety of AK104an anti- PD-1 and CTLA-4 bispecific antibody, in subjects with relapsed or refractory peripheral T cell lymphoma. The subject will receive AK104 450mg Q2W until unacceptable toxicity, confirmed disease progression, withdrawal of consent, or for a maximum …

peripheral t-cell lymphoma

refractory peripheral t-cell lymphoma

cancer

t-cell lymphoma

lymphoma

0 views
19 Feb, 2024